Rep. Gilbert Cisneros (D-CA) Buys HealthEquity (HQY) Stock

Representative Gilbert Cisneros, a Democrat representing California's 31st district in the House, recently added HealthEquity, Inc. ($HQY) to his portfolio. According to a periodic transaction report filed under the STOCK Act, the congressman purchased between $1,001 and $15,000 of the healthcare technology company's stock on May 29, 2026. This disclosure, which reached the public on June 9, 2026, follows a string of other investments the representative made in May across the healthcare and technology sectors.

The Timing of the Trade

Congressman Cisneros executed this buy on May 29, 2026, but the public did not learn of the move until his official report was filed roughly 11 days later. This delay is standard for congressional disclosures, which allow members a window of time to report their personal trading activity. The value of the trade is reported as a range rather than a specific dollar amount, a common practice in these filings. This purchase adds to a busy month for Cisneros, who also reported buying shares in Sensata Technologies and STERIS plc during the same period.

HealthEquity Stock Trends

On this Saturday, HealthEquity shares are trading at $94.75. The stock has shown some resilience, staying above its 200-day moving average of $88.98, though it is currently trading below its 50-day moving average of $99.59. The company has seen a wide range over the past year, hitting a high of $107.62 and a low of $72.76. With a price-to-earnings (P/E) ratio of 34.12, the market is pricing the company at a premium compared to its trailing earnings, though its forward P/E of 17.18 suggests expectations for earnings growth in the year ahead.

Strong Recent Earnings

HealthEquity reported solid financial results in its latest cycle, bringing in $1.36 billion in revenue with a growth rate of 7.6%. The company is profitable, maintaining a net margin of 17.36% and a return on equity of 11.43%. It earned $2.77 per share. Investors are looking toward December 2, 2026, when the company is expected to release its next set of quarterly financial results.

Additional Insider Buying

Cisneros isn't the only one picking up shares. On June 25, 2026, two insiders at HealthEquity also made moves. Wellborn Gayle Furgurson and William Gassen each acquired 2,877 shares of the company. These transactions were not part of a pre-planned Rule 10b5-1 trading schedule. These insider purchases, occurring just weeks after the congressman's trade, suggest a cluster of buying interest from people close to the company's operations and those tracking it from Washington.

Analysts Set New Price Targets

Wall Street analysts have generally maintained a positive outlook on the stock. On September 18, 2026, Barclays kept its Overweight rating and raised its price target to $115.00. Earlier, on August 31, 2026, Deutsche Bank maintained its Buy rating and lifted its target to $142.00. BTIG also reiterated a Buy rating in late August with a $115.00 target. Currently, 15 analysts provide opinions on the stock, resulting in a "strong buy" consensus and an average price target of $119.33.

About HealthEquity, Inc.

HealthEquity provides the technology and platforms that help people manage their health savings accounts (HSAs) and other tax-advantaged benefits like flexible spending accounts (FSAs). Based in Draper, Utah, the company works with employers and health plans to offer investment tools and administrative services for healthcare spending. As more Americans move toward high-deductible health plans, HealthEquity's role as a middleman for health savings has become a central part of the U.S. healthcare finance system.

What to Watch

Market observers often track congressional trades to see which industries or specific companies are catching the eye of lawmakers. While these filings are backward-looking and do not represent a recommendation to buy or sell, they provide a window into the personal financial decisions of those in government. Investors will likely keep an eye on the upcoming December earnings report to see if the company's growth justifies the recent interest from both insiders and political figures.